Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas

Vemurafenib (PLX4032), a selective inhibitor of Braf, has been FDA-approved for the treatment of unresectable or metastatic melanoma in patients with Braf(V600E) mutations. Many patients treated with vemurafenib initially display dramatic improvement, with decreases in both risk of death and tumor p...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fang, Cao, Juxiang, Wu, Jinxiang, Sullivan, Kayleigh, Shen, James, Ryu, Byungwoo, Xu, Zhixiang, Wei, Wenyi, Cui, Rutao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744462/
https://www.ncbi.nlm.nih.gov/pubmed/23344460
http://dx.doi.org/10.1038/jid.2013.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744462/
https://www.ncbi.nlm.nih.gov/pubmed/23344460
http://dx.doi.org/10.1038/jid.2013.32

Ejemplares similares